These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 37078495)

  • 1. Equivalence of plasma p-tau217 with cerebrospinal fluid in the diagnosis of Alzheimer's disease.
    Therriault J; Servaes S; Tissot C; Rahmouni N; Ashton NJ; Benedet AL; Karikari TK; Macedo AC; Lussier FZ; Stevenson J; Wang YT; Fernandez-Arias J; Stevenson A; Socualaya KQ; Haeger A; Nazneen T; Aumont É; Hosseini A; Rej S; Vitali P; Triana-Baltzer G; Kolb HC; Soucy JP; Pascoal TA; Gauthier S; Zetterberg H; Blennow K; Rosa-Neto P
    Alzheimers Dement; 2023 Nov; 19(11):4967-4977. PubMed ID: 37078495
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Head-to-head study of diagnostic accuracy of plasma and cerebrospinal fluid p-tau217 versus p-tau181 and p-tau231 in a memory clinic cohort.
    Mendes AJ; Ribaldi F; Lathuiliere A; Ashton NJ; Janelidze S; Zetterberg H; Scheffler M; Assal F; Garibotto V; Blennow K; Hansson O; Frisoni GB
    J Neurol; 2024 Apr; 271(4):2053-2066. PubMed ID: 38195896
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer's disease and frontotemporal lobar degeneration: a retrospective diagnostic performance study.
    Thijssen EH; La Joie R; Strom A; Fonseca C; Iaccarino L; Wolf A; Spina S; Allen IE; Cobigo Y; Heuer H; VandeVrede L; Proctor NK; Lago AL; Baker S; Sivasankaran R; Kieloch A; Kinhikar A; Yu L; Valentin MA; Jeromin A; Zetterberg H; Hansson O; Mattsson-Carlgren N; Graham D; Blennow K; Kramer JH; Grinberg LT; Seeley WW; Rosen H; Boeve BF; Miller BL; Teunissen CE; Rabinovici GD; Rojas JC; Dage JL; Boxer AL;
    Lancet Neurol; 2021 Sep; 20(9):739-752. PubMed ID: 34418401
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma p-tau231: a new biomarker for incipient Alzheimer's disease pathology.
    Ashton NJ; Pascoal TA; Karikari TK; Benedet AL; Lantero-Rodriguez J; Brinkmalm G; Snellman A; Schöll M; Troakes C; Hye A; Gauthier S; Vanmechelen E; Zetterberg H; Rosa-Neto P; Blennow K
    Acta Neuropathol; 2021 May; 141(5):709-724. PubMed ID: 33585983
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparing the Clinical Utility and Diagnostic Performance of CSF P-Tau181, P-Tau217, and P-Tau231 Assays.
    Leuzy A; Janelidze S; Mattsson-Carlgren N; Palmqvist S; Jacobs D; Cicognola C; Stomrud E; Vanmechelen E; Dage JL; Hansson O
    Neurology; 2021 Oct; 97(17):e1681-e1694. PubMed ID: 34493616
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of Phosphorylated Tau Biomarkers With Amyloid Positron Emission Tomography vs Tau Positron Emission Tomography.
    Therriault J; Vermeiren M; Servaes S; Tissot C; Ashton NJ; Benedet AL; Karikari TK; Lantero-Rodriguez J; Brum WS; Lussier FZ; Bezgin G; Stevenson J; Rahmouni N; Kunach P; Wang YT; Fernandez-Arias J; Socualaya KQ; Macedo AC; Ferrari-Souza JP; Ferreira PCL; Bellaver B; Leffa DT; Zimmer ER; Vitali P; Soucy JP; Triana-Baltzer G; Kolb HC; Pascoal TA; Saha-Chaudhuri P; Gauthier S; Zetterberg H; Blennow K; Rosa-Neto P
    JAMA Neurol; 2023 Feb; 80(2):188-199. PubMed ID: 36508198
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders.
    Palmqvist S; Janelidze S; Quiroz YT; Zetterberg H; Lopera F; Stomrud E; Su Y; Chen Y; Serrano GE; Leuzy A; Mattsson-Carlgren N; Strandberg O; Smith R; Villegas A; Sepulveda-Falla D; Chai X; Proctor NK; Beach TG; Blennow K; Dage JL; Reiman EM; Hansson O
    JAMA; 2020 Aug; 324(8):772-781. PubMed ID: 32722745
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma and CSF biomarkers in a memory clinic: Head-to-head comparison of phosphorylated tau immunoassays.
    Ashton NJ; Puig-Pijoan A; Milà-Alomà M; Fernández-Lebrero A; García-Escobar G; González-Ortiz F; Kac PR; Brum WS; Benedet AL; Lantero-Rodriguez J; Day TA; Vanbrabant J; Stoops E; Vanmechelen E; Triana-Baltzer G; Moughadam S; Kolb H; Ortiz-Romero P; Karikari TK; Minguillon C; Hernández Sánchez JJ; Navalpotro-Gómez I; Grau-Rivera O; María Manero R; Puente-Periz V; de la Torre R; Roquer J; Dage JL; Zetterberg H; Blennow K; Suárez-Calvet M
    Alzheimers Dement; 2023 May; 19(5):1913-1924. PubMed ID: 36370462
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma P-tau181 and P-tau217 in Patients With Traumatic Encephalopathy Syndrome With and Without Evidence of Alzheimer Disease Pathology.
    Asken BM; Tanner JA; VandeVrede L; Mantyh WG; Casaletto KB; Staffaroni AM; La Joie R; Iaccarino L; Soleimani-Meigooni D; Rojas JC; Gardner RC; Miller BL; Grinberg LT; Boxer AL; Kramer JH; Rabinovici GD
    Neurology; 2022 Aug; 99(6):e594-e604. PubMed ID: 35577574
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of immunoassay- with mass spectrometry-derived p-tau quantification for the detection of Alzheimer's disease pathology.
    Therriault J; Woo MS; Salvadó G; Gobom J; Karikari TK; Janelidze S; Servaes S; Rahmouni N; Tissot C; Ashton NJ; Benedet AL; Montoliu-Gaya L; Macedo AC; Lussier FZ; Stevenson J; Vitali P; Friese MA; Massarweh G; Soucy JP; Pascoal TA; Stomrud E; Palmqvist S; Mattsson-Carlgren N; Gauthier S; Zetterberg H; Hansson O; Blennow K; Rosa-Neto P
    Mol Neurodegener; 2024 Jan; 19(1):2. PubMed ID: 38185677
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma Biomarker Strategy for Selecting Patients With Alzheimer Disease for Antiamyloid Immunotherapies.
    Mattsson-Carlgren N; Collij LE; Stomrud E; Pichet Binette A; Ossenkoppele R; Smith R; Karlsson L; Lantero-Rodriguez J; Snellman A; Strandberg O; Palmqvist S; Ashton NJ; Blennow K; Janelidze S; Hansson O
    JAMA Neurol; 2024 Jan; 81(1):69-78. PubMed ID: 38048096
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Head-to-head comparison of clinical performance of CSF phospho-tau T181 and T217 biomarkers for Alzheimer's disease diagnosis.
    Karikari TK; Emeršič A; Vrillon A; Lantero-Rodriguez J; Ashton NJ; Kramberger MG; Dumurgier J; Hourregue C; Čučnik S; Brinkmalm G; Rot U; Zetterberg H; Paquet C; Blennow K
    Alzheimers Dement; 2021 May; 17(5):755-767. PubMed ID: 33252199
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of Plasma Phosphorylated Tau Species With Amyloid and Tau Positron Emission Tomography, Neurodegeneration, Vascular Pathology, and Cognitive Outcomes.
    Mielke MM; Frank RD; Dage JL; Jeromin A; Ashton NJ; Blennow K; Karikari TK; Vanmechelen E; Zetterberg H; Algeciras-Schimnich A; Knopman DS; Lowe V; Bu G; Vemuri P; Graff-Radford J; Jack CR; Petersen RC
    JAMA Neurol; 2021 Sep; 78(9):1108-1117. PubMed ID: 34309632
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Head-to-head comparison of 10 plasma phospho-tau assays in prodromal Alzheimer's disease.
    Janelidze S; Bali D; Ashton NJ; Barthélemy NR; Vanbrabant J; Stoops E; Vanmechelen E; He Y; Dolado AO; Triana-Baltzer G; Pontecorvo MJ; Zetterberg H; Kolb H; Vandijck M; Blennow K; Bateman RJ; Hansson O
    Brain; 2023 Apr; 146(4):1592-1601. PubMed ID: 36087307
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical performance and head-to-head comparison of CSF p-tau235 with p-tau181, p-tau217 and p-tau231 in two memory clinic cohorts.
    Lantero-Rodriguez J; Vrillon A; Fernández-Lebrero A; Ortiz-Romero P; Snellman A; Montoliu-Gaya L; Brum WS; Cognat E; Dumurgier J; Puig-Pijoan A; Navalpotro-Gómez I; García-Escobar G; Karikari TK; Vanmechelen E; Ashton NJ; Zetterberg H; Suárez-Calvet M; Paquet C; Blennow K
    Alzheimers Res Ther; 2023 Mar; 15(1):48. PubMed ID: 36899441
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Performance of plasma p-tau217 for the detection of amyloid-β positivity in a memory clinic cohort using an electrochemiluminescence immunoassay.
    Dyer AH; Dolphin H; O'Connor A; Morrison L; Sedgwick G; Young C; Killeen E; Gallagher C; McFeely A; Connolly E; Davey N; Claffey P; Doyle P; Lyons S; Gaffney C; Ennis R; McHale C; Joseph J; Knight G; Kelly E; O'Farrelly C; Fallon A; O'Dowd S; Bourke NM; Kennelly SP
    Alzheimers Res Ther; 2024 Aug; 16(1):186. PubMed ID: 39160628
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cerebrospinal fluid p-tau181, 217, and 231 in definite Creutzfeldt-Jakob disease with and without concomitant pathologies.
    Emeršič A; Ashton NJ; Vrillon A; Lantero-Rodriguez J; Mlakar J; Gregorič Kramberger M; Gonzalez-Ortiz F; Kac PR; Dulewicz M; Hanrieder J; Vanmechelen E; Rot U; Zetterberg H; Karikari TK; Čučnik S; Blennow K
    Alzheimers Dement; 2024 Aug; 20(8):5324-5337. PubMed ID: 38924651
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phosphorylated tau in Alzheimer's disease.
    Telser J; Grossmann K; Wohlwend N; Risch L; Saely CH; Werner P
    Adv Clin Chem; 2023; 116():31-111. PubMed ID: 37852722
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Bio-Hermes Study: Biomarker database developed to investigate blood-based and digital biomarkers in community-based, diverse populations clinically screened for Alzheimer's disease.
    Mohs RC; Beauregard D; Dwyer J; Gaudioso J; Bork J; MaGee-Rodgers T; Key MN; Kerwin DR; Hughes L; Cordell CB;
    Alzheimers Dement; 2024 Apr; 20(4):2752-2765. PubMed ID: 38415908
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma Aβ42/Aβ40 and phospho-tau217 concentration ratios increase the accuracy of amyloid PET classification in preclinical Alzheimer's disease.
    Rissman RA; Langford O; Raman R; Donohue MC; Abdel-Latif S; Meyer MR; Wente-Roth T; Kirmess KM; Ngolab J; Winston CN; Jimenez-Maggiora G; Rafii MS; Sachdev P; West T; Yarasheski KE; Braunstein JB; Irizarry M; Johnson KA; Aisen PS; Sperling RA;
    Alzheimers Dement; 2024 Feb; 20(2):1214-1224. PubMed ID: 37932961
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.